The Effects of a Probiotic (Bacillus clausii) in Acute KidneyInjury in a Rat Model of LPS-Induced Endotoxemia

Objective: This study aims to examine the role of a probiotic bacterium, Bacillus clausii, on oxidative stress in a lipopolysaccharide (LPS)-induced acute kidney injury (AKI) rat model.Materials and Methods: The rats were divided into four groups: Control group, LPS group (1.5 mg/kg, LPS), Probiotic+LPS group in which LPS was given after administration of Bacillus clausii as a probiotic for 21 days, and Probiotic group. The kidneys of the rats were removed 24 hours after LPS injection. Total antioxidant status, total oxidant status, oxidative stress index, malondialdehyde and myeloperoxidase (MPO) values were biochemically determined in the kidneys. Furthermore, the kidney tissue samples were immunohistochemically stained for interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α expression, and leukocyte distribution.Results: Endotoxemia caused an increase in oxidative stress (p

PDF

___

1. Cani PD. Human gut microbiome: hopes, threats and promises. Gut 2018; 67(9): 1716-25.
2. Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 2013; 64: 145-63.
3. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449(7164): 804-10.
4. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019; 7(1): 14.
5. Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol 2017; 35: 8-15.
6. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 2014; 16(7): 1024-33.
7. Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and ‘dysbiosis therapy’ in critical illness. Curr Opin Crit Care 2016; 22(4): 347-53.
8. Kho ZY, Lal SK. The human gut microbiome - A potential controller of wellness and disease. Front Microbiol 2018; 9: 1835.
9. Davison JM, Wischmeyer PE. Probiotic and synbiotic therapy in the critically ill: State of the art. Nutrition 2019; 59: 29-36.
10. Ciprandi G, Tosca MA, Milanese M, Caligo G, Ricca V. Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: a pilot study. Pediatr Allergy Immunol 2004; 15(2): 148-51.
11. Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007; 46(3): 841-50.
12. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57(6): 1470-81.
13. FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food London, Ontario, Canada, April 30 and May 1, 2002.
14. Elshaghabee FMF, Rokana N, Gulhane RD, Sharma C, Panwar H. Bacillus as potential probiotics: status, concerns, and future perspectives. Front Microbiol 2017; 8: 1490.
15. Cenci G, Trotta F, Caldini G. Tolerance to challenges miming gastrointestinal transit by spores and vegetative cells of Bacillus clausii. J Appl Microbiol 2006; 101(6): 1208-15.
16. Jenson I., Encyclopedia of food microbiology (Second Edition), Editor(s): Carl A. Batt, Mary Lou Tortorello, Bacillus, Introduction, London, Academic Press, 2014, Pages 111-7.
17. Delbrassinne L., Mahillon J., Encyclopedia of food and health, Editor(s): Benjamin Caballero, Paul M. Finglas, Fidel Toldrá, Bacillus: Occurrence, Academic Press, 2016, Pages 307-11.
18. Khatri I, Sharma G, Subramanian S. Composite genome sequence of Bacillus clausii, a probiotic commercially available as Enterogermina®, and insights into its probiotic properties. BMC Microbiol 2019; 19(1): 307.
19. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41(8): 1411-23.
20. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care 2014; 20(6): 588-95.
21. Gómez H, Kellum JA. Sepsis-induced acute kidney injury. Curr Opin Crit Care 2016; 22(6): 546-53.
22. Rabb H, Pluznick J, Noel S. The microbiome and acute kidney injury. Nephron 2018; 140(2): 120-3.
23. Stavropoulou E, Kantartzi K, Tsigalou C, Konstantinidis T, Romanidou G, Voidarou C, et al. Focus on the gut-kidney axis in health and disease. Front Med (Lausanne) 2021; 7: 620102.
24. Al-Harbi NO, Nadeem A, Ahmad SF, Alotaibi MR, Al Asmari AF, Alanazi WA, et al. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol 2018; 58: 24-31.
25. Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 2015; 26(8): 1877-88.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-8.
27. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87(6): 1344-50.
28. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150(1): 76-85.
29. Legrand M, Bezemer R, Kandil A, Demirci C, Payen D, Ince C. The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. Intensive Care Med 2011; 37(9): 1534-42.
30. Bonavia A, Singbartl K. A review of the role of immune cells in acute kidney injury. Pediatr Nephrol 2018; 33(10): 1629-39.
31. Jang HR, Gandolfo MT, Ko GJ, Satpute S, Racusen L, Rabb H. Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009; 297(5): F1457-65.
32. Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut 2020; 69(12): 2131-42.
33. Ávila PRM, Michels M, Vuolo F, Bilésimo R, Burger H, Milioli MVM, et al. Protective effects of fecal microbiota transplantation in sepsis are independent of the modulation of the intestinal flora. Nutrition 2020; 73:110727.
34. Khanna S, Bishnoi M, Kondepudi KK, Shukla G. Isolation, characterization and anti-inflammatory mechanism of probiotics in lipopolysaccharide-stimulated RAW 264.7 macrophages. World J Microbiol Biotechnol 2020; 36(5): 74.
35. Lee TH, Park D, Kim YJ, Lee I, Kim S, Oh CT, et al. Lactobacillus salivarius BP121 prevents cisplatininduced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and pcresol sulfate via alleviating dysbiosis. Int J Mol Med 2020; 45(4): 1130-40.
36. Yılmaz M, Erdem AO. The protective role of probiotics in sepsis-induced rats. Ulus Travma Acil Cerrahi Derg 2020; 26(6): 843-6.
37. Kadafi KT, Wibowo S. Differences in systemic humoral immune response among Balb/c mice administered with probiotic, LPS Escherichia coli, and probiotic-LPS E. coli. Iran J Microbiol 2019; 11(4): 294-9.
38. Ripert G, Racedo SM, Elie AM, Jacquot C, Bressollier P, Urdaci MC. Secreted compounds of the probiotic Bacillus clausii strain O/C inhibit the cytotoxic effects induced by Clostridium difficile and Bacillus cereus toxins. Antimicrob Agents Chemother 2016; 60(6): 3445-54.
39. Paparo L, Tripodi L, Bruno C, Pisapia L, Damiano C, Pastore L, et al. Protective action of Bacillus clausii probiotic strains in an in vitro model of Rotavirus infection. Sci Rep 2020; 10(1): 12636.
40. Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol 2004; 38(6 Suppl): S86-90.
41. Di Caro S, Tao H, Grillo A, Franceschi F, Elia C, Zocco MA, et al. Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol 2005; 17(9): 951-60.
42. Neag MA, Catinean A, Muntean DM, Pop MR, Bocsan CI, Botan EC, et al. Probiotic Bacillus spores protect against acetaminophen induced acute liver injury in rats. Nutrients 2020; 12(3): 632.
43. Patel C, Patel P, Acharya S. Therapeutic prospective of a spore-forming probiotic-Bacillus clausii UBBC07 against acetaminophen-induced uremia in rats. Probiotics Antimicrob Proteins 2020; 12(1): 253-8.
44. Mazza, P. The use of Bacillus subtilis as an antidiarrhoeal microorganism. Bollettino chimico farmaceutico 1994; 133.1: 3-18.
45. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004; 20(10): 1181-8.
46. Plomer M, Iii Perez M, Greifenberg DM. Effect of Bacillus clausii capsules in reducing adverse effects associated with Helicobacter pylori eradication therapy: A randomized, double-blind, controlled trial. Infect Dis Ther 2020; 9(4): 867-78.